Abstract Autoimmune hepatitis (AIH) is a complex autoimmune disease characterized by immune-mediated destruction of hepatic parenchyma which can result in cirrhosis, liver failure, and death. Current American Association for the Study of Liver Diseases (AASLD) and European Association for the Study of Liver (EASL) guidelines recommend corticosteroids alone or in combination with azathioprine as first-line treatment strategies. However, a significant proportion of patients may not be able to tolerate or achieve complete biochemical response with these options. In this article, we discuss approaches to these patients and other challenging AIH patient groups such as the asymptomatic, pregnant, elderly, and liver transplant recipients.
Introduction
Autoimmune hepatitis (AIH) is a female-predominant condition characterized by immune-mediated destruction of liver parenchyma and presence of peripheral autoantibodies [1••, 2] . Waldenström first described this disease in a group of young females with hypergammaglobulinemia over 60 years ago [3] . Despite forward progress in diagnosis and therapeutic strategies, variable clinical and phenotypic presentations have prevented the formation of standardized algorithmic treatment for all patients. Similar to other autoimmune liver diseases [4, 5] , all AIH is not the same; high-risk populations such as African Americans [6] or those with early disease onset [7•, 8•] , incomplete normalization of liver tests [7•] , and advanced disease at diagnosis [8•, 9] have worse overall survival.
AIH was the first chronic liver disease in which medical treatment was associated with improved survival [10] , yet an This article is part of the Topical Collection on Liver * Samer Gawrieh sgawrieh@iu.edu individualized therapeutic approach has not yet been established. Management principles even among experts in this evolving field remain heterogeneous especially beyond accepted first-line therapies. Much like any rare disease, the variation in therapeutic approaches is the result of small retrospective studies, poor understanding of disease-associated immunologic mechanisms, and wide knowledge gaps in disease pathogenesis. The clarification of evidence-based strategies is paramount, as recent epidemiologic data suggest a rising incidence of AIH [11••] . Strategic AIH goals of normalization of liver inflammation, prevention of subsequent parenchymal insult, and inhibition of fibrosis progression or reversal of existing scar are similar to those of any chronic liver disease. This review will highlight these therapeutic aims while clarifying the approach to challenging groups of adult AIH patients.
Beyond Guideline-Recommended First-Line Treatment Strategies
The current American Association for the Study of Liver Diseases (AASLD) and European Association for the Study of Liver (EASL) recommend treatment of disease-related inflammation with either high-dose corticosteroids alone or in combination with azathioprine (AZA) [1••, 12] . Therapeutic endpoints have become more stringent in updated guidelines, and treating clinicians should now target normalization of both aspartate aminotransferase (AST) and alanine aminotransferase (ALT) as well as immunoglobulin G (IgG) in order to optimize transplant-free survival [7•] . Unfortunately, not all AIH patients will have favorable biochemical responses to first-line regimens because of medication intolerance (10 %) [12] , incomplete response (15 %) [12, 13•] , and treatment failure (9 %) [14] .
Treatment Intolerant
The inability to normalize liver transaminases and IgG due to intolerance (side effects) of medication requires urgent exploration of other treatment agents given the increased risk of fibrosis progression and worse survival [15, 16] . Fortunately, AIH maintenance armaments have expanded in recent years, and multiple reports of nonstandard therapies in challenging patient groups are available. Intolerance to recommended first-line therapy, AZA and prednisone, is a significant cause for cessation of therapy in up to 10 % of patients related to physical, somatic, or hematologic findings [12] .
There is currently no consensus on the optimal second-line choice for AZA intolerance. Mycophenolate mofetil (MMF) is the most studied second-line agent to date, and observational data suggests it is tolerated in 54-74 % of patients in this group [17, 18•, 20, 21] . However, 6-mercaptopurine (6-MP), a molecule formed from nonenzymatic degradation of the nitroimidazol group from AZA, could also be a viable treatment strategy subsequent to AZA because of retained immunosuppressive properties (Table 1) . In studies of inflammatory bowel disease, up to 60 % of patients intolerant to AZA are able to tolerate 6-MP [19, 20] . A recent study by Hübener et al. [13•] retrospectively examined 20 AZAintolerant AIH patients, largely from gastrointestinal side effects, from two large European referral centers. 6-MP was tolerated well by 15 (75 %) patients and resulted in complete and partial biochemical response in eight and seven patients, respectively. Therefore, 6-MP may have tolerance rates similar to MMF and could be considered as an option for this group of patients [1••, 12] . We prefer challenging AZAintolerant patients with 6-MP (25 mg daily and increasing to 50 mg daily if tolerated), as it could help avoid risk of teratogenicity in females that are pregnant or become pregnant while taking MMF as well as provide cost savings. Furthermore, as a downstream immunologically active product of the AZA, 6-MP may provide much of the survival benefits as its well-studied parent compound.
Patients with intolerance or drug-induced complications from systemic corticosteroid therapy [21] are also a challenging cohort of patients with difficult-to-treat AIH (Table 1) . Corticosteroids have shown survival benefit with or without AZA since the 1960s, yet AZA alone for induction therapy was associated with an excess of mortality in early clinical trials [10, 22] . Budesonide, a next-generation corticosteroid, may have a critical role in those with systemic corticosteroid contraindications such as patient with osteoporosis, poorly controlled diabetes or hypertension, or unstable mental illness. The results from a 6-month, blinded, phase IIb trial including AIH patients without cirrhosis on budesonide (3 mg, either three times or two times daily) and AZA were published in 2010 [23] . In 6 months, the combination budesonide and AZA group had both higher frequency of normalized liver tests (60 vs 38.8 %) and less steroid-related side effects (28 vs 54.4 %) compared to the standard therapy group prednisone and AZA. This prospective randomized control trial was criticized because of lower-than-expected remission rates on prednisone that may have been due to scheduled prednisone weaning, a relatively low dose of prednisone in the control arm, short-term follow-up, and no histologic comparison of outcomes. Budesonide therapy in AIH requires consideration of no defined long-term outcomes, unclear dose scheduling, and contraindication in patients with cirrhosis and those with portosystemic collaterals [1••] . We have observed good response rates in some AIH patients treated with combination therapy including budesonide in place of prednisone. However, we have also witnessed a few incomplete responses despite optimization of the maintenance agent and agree with the most recent EASL guidelines that a change to systemic corticosteroids is commonly beneficial in this group.
Incomplete and Nonresponders
Incomplete response to a treatment regimen is defined by inadequate improvement of clinical symptoms, biochemical data (AST/ALT and IgG), and possibly histologic findings. Current guidelines [1••, 12] suggest normalization of aminotransferases and IgG levels as a key therapeutic aim, as the clinical impact of incomplete response has been linked to fibrosis progression, liver-related death, or requirement of liver transplantation [7•, 24, 25] .
Patients are identified as incomplete responders if they fail to normalize liver tests and IgG within 3 years according to the AASLD guidelines [12] (Table 1) . It is to be determined if fulfillment of AALSD and EASL treatment goals has dramatic impact on long-term outcomes prospectively. In retrospective reviews, it seems that meeting more stringent response criteria may better predict those with excellent outcomes [26] . In fact, utilization of early biochemical response may have merit in this arena, as Kanzler et al. observed that patients exhibiting a biochemical response in only 3 months have excellent long-term survival [27] . Furthermore, incomplete normalization of ALT within 6 months of therapy in a study of 133 AIH patients from New Zealand was independently associated with poor outcomes [7•] . However, it must be observed that normal liver tests may not be the best surrogate for hepatic inflammation; as disagreement with histologic activity is relatively common according to study by Dhaliwal et al. [28•] . In that study of 120 AIH patients with normal ALT and globulin levels at 6 months, persistent histologic inflammation was observed in 46 % of patient biopsy specimens. Furthermore, those with continued inflammation had less frequent regression of fibrosis and excess mortality compared to patients with histologic normalization.
The demarcation of incomplete response requires further management considerations beyond that of biochemical follow-up. In fact, the failure to meet treatment goals, at treatment initiation or in follow-up, should prompt examination for concurrent liver disease (including overlap phenomenon, Fig. 1 ), drug-induced liver injury, treatment compliance, inadequate pharmacologic therapy, and accuracy of diagnosis. Consideration of coexistent autoimmune liver diseases, primary sclerosing cholangitis (PSC), and primary biliary cholangitis (PBC) is necessary, particularly among individuals with evolution of cholestasis. Overlap phenomenon is not rare in AIH groups, as a recent cross-sectional study of over 1300 AIH patients from the Netherlands identified PBC and PSC in 9 and 6 % of AIH patients, respectively [29•] . Liver biopsy plays an important role not only initially at the time of establishing the diagnosis of AIH, but also in cases with incomplete response to optimal therapy. Typical (interface hepatitis, lymphoplasmacytic infiltrates, hepatic rosette formation, and emperipolesis) and compatible histologic findings on liver biopsy are critical to confirming the diagnosis AIH [1••] and clarifying the presence or absence of alternative or coexisting hepatic disease. However, there are no pathognomonic AIH features on biopsy, and histologic findings should lend support or opposition to diagnosis.
Furthermore, careful exposure and drug histories (including AZA), as well as pinpointing other contributing comorbidities such as the metabolic syndrome, should raise suspicions for additive processes (Table 1 ). Coexisting nonhepatic conditions should also be examined and optimized in order to provide best care, as incomplete responders have more anxiety, depression, and avoidant relationship styles [30] . Thus, aggressive identification and treatment of anxiety and depression, as well as the education of medical compliance is a critical therapeutic step in this distinct group. Monitoring of AZA metabolites (6-thioguanine nucleotide (6-TGN) and 6-methyl mercaptopurine (6-MMP)) in AZA-treated patients could also identify a proportion of Despite elimination of contributing hepatic disease or insults, optimization of first-line therapies, and assurance of medical adherence, abnormal liver tests will be present in 9-34 % of treated patients at 2 years [14, 27] . These patients, along with those intolerant and failing (minimal clinical and laboratory improvement in several weeks without liver failure with standard first-line therapy [1••] ) standard therapy, are candidates for alternative immunosuppressive treatments. The more common strategies including MMF, sirolimus/ everolimus, tacrolimus, and cyclosporine have encouraging results in regard to biochemical improvement. However, extrapolation of these agents to practice must be cautiously undertaken as they are founded primarily on small retrospective case series with heterogeneous endpoints.
MMF, a purine antagonist widely used in the setting of liver transplantation, has been utilized in a number of small retrospective studies including patients with AIH with AZA intolerance, incomplete response, and failure [17, 18•, 34] . MMF (goal 1500-3000 mg in divided doses per day) seems to be effective as a second-line agent for patients with AZA intolerance. A small retrospective study showed that complete response rate was observed in 8 out of 9 patients who were intolerant to AZA [34] . In the same study, patients switched to MMF after treatment failure with AZA were only able to gain biochemical improvement, but not complete response. A similar observation was made by Hennes et al., as 75 % of patients with AZA failure did not respond to MMF [17] . Only recently has MMF been considered for first-line AIH therapy, and results suggest that it may be an effective and welltolerated medication with 88 % of patients obtaining biochemical normalization within the first few months [35] . However, there is no long-term survival data for MMF, nor are the implications of its role as a potential teratogen during pregnancy commonly considered. Utilization of MMF among women of child-bearing age necessitates the documented discussion of increased risk of spontaneous abortion and major birth defects [36] associated with its use in pregnancy. We require at-risk patients to use two forms of birth control and periodic urine pregnancy tests. GI symptoms (e.g., nausea, dyspepsia and diarrhea), headache, and bone marrow suppression are among the common side effects seen with MMF use. If supportive measures do not alleviate these symptoms, MMF dose reduction should be considered next.
Mammalian target of rapamycin (mTOR) inhibitors, such as sirolimus and everolimus, work to modulate the expansion and survival of activated lymphocytes. These agents were initially reported in the post-transplant experience with AIH [37] , yet this experience led to their introduction in challenging AIH patients. A recent small US report included five AIH patients with first-line (three patients with second-line MMF as well) failure treated with sirolimus (2 mg per day) and titrated trough levels of 10-20 ng/dL. Four (80 %) of these patients showed an improvement in liver tests, and two (40 %) patients had normalization [38] . Similarly, everolimus showed some efficacy for AIH patients with treatment nonresponse and intolerance. In one study, 43 % of patients had normal ALT levels and 57 % had ALT levels less than 55 international units after 5 months of therapy [39] . While experience with patients that may be rescued from incomplete response with dose adjustment. 6-TGN concentrations more than 220 pmol per 8 × 10
8 red blood cells have been associated with biochemical remission [31] . Elevated 6-MMP levels (>5700 pmol per 8 × 10 8 ) can also contribute to associated symptoms of nausea, anorexia, and influenza-like symptoms [32] , thereby impacting compliance. Allopurinol, through inhibition of xanthine oxidase, represents a therapeutic approach in patients with increased 6-MMP and low 6-TGN, as it produces preferential AZA metabolism by the thiopurine methyltransferase enzymatic pathway toward 6-TGN [33] . mTOR inhibitors in AIH is currently limited, they may represent a treatment option in AIH patients with recent history of malignancy based on their anti-proliferative effect [40] .
Calcineurin inhibitors, such as cyclosporine and tacrolimus, represent the most extensively studied drug class in the treatment of refractory AIH cases. However, published experiences are marked by small treatment numbers and limited follow-up data. The literature contains ten reports of 133 patients utilizing cyclosporine as initial and second-line agent for incomplete response and failure and has been commonly effective in over 90 % of patients [41] . In one study, five AIH patients with poor response to AZA and corticosteroids were treated with cyclosporine at 2-3 mg/kg/day which resulted in biochemical remission of 80 % of patients in 3 months [42] . Tacrolimus has also shown some benefit in this hard-to-treat AIH group, as studies have supported improvement by any measure in 98 % of patients [41] . The most recent experience with tacrolimus in this setting included 13 patients with incomplete response or failure at a single large center, where 12 obtained normalization of liver enzymes (mean trough 6.0 ng/mL) [43] .
Acute Severe Presentation
Arguably, one of the most challenging groups of AIH is that with acute severe hepatitis, with or without liver failure. Published experience is limited and there are common associations with outcomes of death or transplant in these patients [44, 45] Approximately half of treated and all of the untreated patients required liver transplantation, yet there was no difference in sepsis episodes or mortality between the groups. Key prognostic classifications are still not available for this high-risk group, as severity of liver failure may play a role in steroid responsiveness [47] . In fact, a study of 40 South American patients with fulminant AIH revealed that corticosteroid failure was much more likely among those with higher MELD scores and encephalopathy grade 3 or higher [48••] . Utilization of corticosteroids in an acute severe presentation, preferably at high dose intravenously, requires close observation of clinical improvement or deterioration and infection. Early evaluation and listing for liver transplantation should be done for patients presenting with acute liver failure while response to therapy is assessed.
Pregnancy
The approach to pregnancy in AIH patients requires close attention, as disease development or flare during or after pregnancy can pose a significant risk to both mother and baby. A recent report of 83 pregnancies in 53 women with AIH revealed maternal complications and disease flares in 38 and 33 %, respectively. AIH flares (worsening liver inflammation) were more likely to occur in patients who were not on therapy or had a flare in the year prior to conception [49] . An earlier study of 22 women with a total of 44 pregnancies found that over half had disease flares after delivery and almost a quarter flared during pregnancy [50] . A variety of approaches have been utilized in pregnant AIH patients prior to or at conception including discontinuation of all immunosuppressants or modification of long-term maintenance medications. Pharmacologic alterations have been focused on minimizing risk to baby; however, the aforementioned data suggests that maternal disease control remains important throughout pregnancy and after delivery. AZA remains a US Food and Drug Association category D medication in pregnancy. Yet, multiple retrospective studies have shown no increase in birth defects, stillbirths, or fetal malformations with use of AZA [50] [51] [52] . A similar safety profile of AZA in pregnancy has been shown among inflammatory bowel disease patients [53] . Mindful consideration of calcineurin inhibitor use in AIH during pregnancy should also be exercised, as posttransplant data has suggested favorable pregnancy outcomes in this group including patients treated with tacrolimus (60 %) and cyclosporine A (38 %) [54] .
Despite the theoretical increase in anti-inflammatory cytokines secondary to rising estrogen levels [55] , we routinely counsel pregnant or patients considering pregnancy with AIH about the risk and benefits of maintaining remission with AZA or corticosteroids throughout pregnancy in accordance with the above data and current EASL guidelines [1••] . Optimal disease control in the year leading up to pregnancy and careful monitoring for disease activity after delivery are also suggested. MMF should be withdrawn prior to conception and should not be used during pregnancy as it has been associated with increased teratogenicity [56] . We try to avoid MMF use in child-bearing patients, yet if necessary, we carefully counsel patients on the risk of this drug in pregnancy, ensure two forms of birth control, and engage in frequent urine pregnancy testing.
Asymptomatic and Elderly
Approximately one third of AIH patients will present without complaints [11••, 26, 29•] , commonly with findings of slightly abnormal liver tests from routine laboratory work completed for other indications. Despite the range of clinical variability between asymptomatic and symptomatic patients at presentation, similar degrees of lobular hepatitis and bridging fibrosis have been observed at diagnosis. Furthermore, many with a mild asymptomatic presentation will become symptomatic and develop a variety of symptoms such as malaise, nausea, abdominal pain, pruritus, or jaundice. Left untreated, a lower overall survival can be expected for these patients [57] . Improvement of hepatic fibrosis, including cirrhosis, in both groups is achievable, as observed in 57 % of treated AIH patients with paired liver biopsies [58] . Among those diagnosed and treated early, approximately 80 % can expect fibrosis resulting from hepatic inflammation to be prevented or delayed [59] . In fact, in this study from the Mayo Clinic with 87 patients, fibrosis scores improved in 53 % and remained stable in 26 %. As expected, improvement of fibrosis scores was related to improvement in histologic activity indices during the approximately 4-year follow-up. Therefore, we recommend aggressively treating patients with mild asymptomatic disease in order to minimize symptomatic disease, improve overall survival, and prevent fibrosis progression.
The decision to treat older patients with asymptomatic disease and mild inflammation is still debatable, as the medication risks may outweigh the theoretical benefit of treatment. One study showed 67 % overall 10-year survival of untreated mild asymptomatic patients [60] . An uncontrolled study of 31 asymptomatic patients (half did not receive therapy) showed no difference in survival among the nontreated patients and the rest of the cohort [9] . Elderly patients commonly constitute a large proportion of asymptomatic patients at presentation, but have been shown to present with increased frequency of advanced fibrosis [60, 61] . We offer treatment to those with advanced fibrosis and evidence of significant inflammatory activity on liver biopsy. However, in the elderly with mild activity and early fibrosis, the decision to treat should be carefully considered, and exercising pharmaceutical reluctance, especially among patients with significant comorbidities, remains reasonable.
Cirrhosis
Treatment of AIH patients with advanced fibrosis and cirrhosis remains critical if not contraindicated by associated comorbidities. Cirrhosis at diagnosis has been observed to be a predictor of reduced survival and is associated with need for liver transplantation [8•] . Findings of inflammatory activity on biopsy among patients with cirrhosis necessitate treatment, as failure to normalize histologic inflammation is associated with less fibrosis regression and also worsened overall survival [28•] . In fact, improvement of fibrosis may explain previous findings of similar survival rates between patients with and without cirrhosis at diagnosis [62] . However, we commonly withhold therapy in cirrhotic AIH patients without histologic inflammation on biopsy (burned out cirrhosis), as the impact in overall outcome is likely to be minimal at best and may even increase risk of drug-related side effects [9, 63] .
Recurrent AIH After Orthotropic Liver Transplantation
Liver transplantation should be considered in patients with AIH when signs of fulminant failure, hepatic decompensation, or liver cancer occur. The recurrence of AIH (rAIH) after transplantation is common and ranges from 8 to 12 % at 1 year after transplantation [64] . The 5-year risk of recurrence is 36-68 %. Despite a high rate of recurrence, graft failure requiring re-transplantation occurs in only 13-23 % and the 5-year survival of adults with recurrent AIH is excellent at 89-100 % [12] . Given these statistics, the possibility of recurrence should not preclude the prospect of liver transplantation for a suitable candidate.
Particular patient populations may be at higher risk for recurrent AIH after transplantation. Studies show that recurrent AIH tends to be more frequent in HLA-DR3-positive transplant recipients [65, 66] . HLA mismatching may also be a significant factor in rAIH [67] ; however, given the scarcity of organ donors, we do not recommend HLA matching for liver transplantation. A recent study demonstrated that severity of original disease correlates with risk of aggressive rAIH [67, 68] . Patients with higher IgG, AST, and ALT are more likely to have recurrent AIH, suggesting that incomplete suppression at the time of transplant may contribute to rAIH. Diagnosis of rAIH can be difficult, as this entity may be found with normal liver tests [69] . Some authors suggest that protocol liver biopsies may be used to identify clinically silent remission [69] ; however, this is not our common practice. When a biopsy is performed, histology should demonstrate interface hepatitis with plasma cells and lymphocytes but without endotheliitis or ductilitis. One might expect less recurrent autoimmune disease since transplant patients are maintained on immunosuppressive therapy; however, rAIH can be more aggressive than prior to transplantation. Many patients will require multidrug immunosuppression longterm including a calcineurion inhibitor, MMF, and corticosteroids with or without an mTOR inhibitor [70] .
Conclusions
AZA and corticosteroids remain a well-established and guideline-driven approach to AIH treatment [1••, 12] . However, second-line treatment strategies for AIH and distinctive patient groups at risk for disease-related complications remain a major challenge. Beyond second-line therapy considerations, AIH patient populations such as those with an acute severe or asymptomatic presentation, pregnancy, advanced age, cirrhosis, and rAIH also represent special cohorts where limited study numbers have been unable to clarify an algorithmic approach. We propose an individualized strategy based on current literature and guidelines to address these difficult-to-manage cases.
AIH represents a dynamic field of study with a breadth of unmet research needs. Insight into the nuances of AIH management may become transparent with further dissection of key genetic underpinnings and environmental risk factors.
Until then, AIH will require continued study, collaboration of investigators, and access to large populations with AIH to accumulate the best clinical evidence. Our center has formed the Autoimmune Hepatitis Research Network (www. facebook.com/groups/autoimmunehep) and Autoimmune H e p a t i t i s A s s o c i a t i o n ( w w w. f a c e b o o k . c o m / autoimmunehepatititsassociation and www.aihep.org) in 2014 with the hope that social media use as a research tool will make research opportunities for AIH easily accessible to proactive patients and interested academic centers [71•] .
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